Literature DB >> 18045848

Mortality of former crocidolite (blue asbestos) miners and millers at Wittenoom.

A W Musk1, N H de Klerk, A Reid, G L Ambrosini, L Fritschi, N J Olsen, E Merler, M S T Hobbs, G Berry.   

Abstract

BACKGROUND: Blue asbestos was mined and milled at Wittenoom in Western Australia between 1943 and 1966.
METHODS: Nearly 7000 male workers who worked at the Wittenoom mine and mill have been followed up using death and cancer registries throughout Australia and Italy to the end of 2000. Person-years at risk were derived using two censoring dates in order to produce minimum and maximum estimates of asbestos effect. Standardised mortality ratios (SMRs) compare the mortality of the former Wittenoom workers with the Western Australian male population.
RESULTS: There have been 190 cases of pleural and 32 cases of peritoneal mesothelioma in this cohort of former workers at Wittenoom. Mortality from lung cancer (SMR = 1.52), pneumoconiosis (SMR = 15.5), respiratory diseases (SMR = 1.58), tuberculosis (SMR = 3.06), digestive diseases (SMR = 1.47), alcoholism (SMR = 2.24) and symptoms, signs and ill defined conditions (SMR = 2.00) were greater in this cohort compared to the Western Australian male population.
CONCLUSION: Asbestos related diseases, particularly malignant mesothelioma, lung cancer and pneumoconiosis, continue to be the main causes of excess mortality in the former blue asbestos miners and millers of Wittenoom.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18045848     DOI: 10.1136/oem.2007.034280

Source DB:  PubMed          Journal:  Occup Environ Med        ISSN: 1351-0711            Impact factor:   4.402


  9 in total

Review 1.  Stomach cancer mortality among workers exposed to asbestos: a meta-analysis.

Authors:  Wen-jia Peng; Xian-jie Jia; Bing-gan Wei; Lin-sheng Yang; Ying Yu; Lei Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-13       Impact factor: 4.553

2.  No dose-dependent increase in fracture risk after long-term exposure to high doses of retinol or beta-carotene.

Authors:  G L Ambrosini; A P Bremner; A Reid; D Mackerras; H Alfonso; N J Olsen; A W Musk; N H de Klerk
Journal:  Osteoporos Int       Date:  2012-09-18       Impact factor: 4.507

Review 3.  Applying definitions of "asbestos" to environmental and "low-dose" exposure levels and health effects, particularly malignant mesothelioma.

Authors:  B W Case; J L Abraham; G Meeker; F D Pooley; K E Pinkerton
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

4.  Estimating the asbestos-related lung cancer burden from mesothelioma mortality.

Authors:  V McCormack; J Peto; G Byrnes; K Straif; P Boffetta
Journal:  Br J Cancer       Date:  2012-01-10       Impact factor: 7.640

5.  Malignant mesotheliomas in former miners and millers of crocidolite at Wittenoom (Western Australia) after more than 50 years follow-up.

Authors:  G Berry; A Reid; P Aboagye-Sarfo; N H de Klerk; N J Olsen; E Merler; P Franklin; A W Musk
Journal:  Br J Cancer       Date:  2012-02-07       Impact factor: 7.640

6.  Cancer Attributable to Asbestos Exposure in Shipbreaking Workers: A Matched-Cohort Study.

Authors:  Wei-Te Wu; Yu-Jen Lin; Chung-Yi Li; Perng-Jy Tsai; Chun-Yuh Yang; Saou-Hsing Liou; Trong-Neng Wu
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

7.  Stomach cancer and occupational exposure to asbestos: a meta-analysis of occupational cohort studies.

Authors:  L Fortunato; L Rushton
Journal:  Br J Cancer       Date:  2015-04-30       Impact factor: 7.640

Review 8.  Occupational exposure to asbestos and cardiovascular related diseases: A meta-analysis.

Authors:  Yi Rong; Xin Luo; Zhihong Zhang; Xiuqing Cui; Yuewei Liu; Weihong Chen
Journal:  Prev Med Rep       Date:  2015-10-21

9.  ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms.

Authors:  D James Morré; Brandon Hostetler; David J Taggart; Dorothy M Morré; A W Musk; Bruce W S Robinson; Jenette Creaney
Journal:  Clin Proteomics       Date:  2016-01-22       Impact factor: 3.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.